Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease.

Trial Profile

Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacokinetics
  • Acronyms ECGPPA

Most Recent Events

  • 28 Nov 2011 Trial phase changed from II to I and actual patient number is 20 as reported by ClinicalTrials.gov.
  • 28 Nov 2011 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.
  • 28 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top